What is palisadebio?
Palisade Bio is a late-stage biopharmaceutical company focused on developing novel therapies for patients suffering from acute and chronic gastrointestinal complications, particularly those arising from post-operative digestive enzyme damage. The company's lead asset, LB1148, is a protease inhibitor currently in Phase 3 readiness. Previous Phase 2 trials have indicated LB1148's potential to mitigate abdominal adhesions and facilitate the restoration of bowel function post-surgery, demonstrating a statistically significant improvement in the return to bowel function and a reduction in ICU and hospital stays compared to placebo. The company's therapeutic approach targets a critical unmet need in surgical recovery.
How much funding has palisadebio raised?
palisadebio has raised a total of $4.4M across 2 funding rounds:
Stock/Share Issuance
$3.9M
Private Equity
$500K
Stock/Share Issuance (2025): $3.9M, investors not publicly disclosed
Private Equity (2026): $500K led by Crohn's & Colitis Foundation
Key Investors in palisadebio
Crohn's & Colitis Foundation
The Crohn's & Colitis Foundation is a non-profit organization dedicated to finding cures for Crohn's disease and ulcerative colitis and improving the quality of life for affected individuals. Their involvement suggests a strategic interest in gastrointestinal health advancements.
What's next for palisadebio?
The recent major strategic investment provides Palisade Bio with significant capital to advance its lead asset, LB1148, through its upcoming Phase 3 trials. This funding is expected to accelerate the company's path toward potential regulatory approval and commercialization. The focus will likely be on executing the clinical development plan efficiently and preparing for market entry, positioning Palisade Bio to address a substantial market opportunity in post-operative gastrointestinal care. The company's progress indicates a strong trajectory for growth and innovation in the biopharma sector.
See full palisadebio company page
